CVMCEL SCI CORP

NYSE cel-sci.com


$ 1.30 $ -0.13 (-9.29 %)    

Friday, 17-May-2024 15:59:59 EDT
QQQ $ 451.63 $ -0.22 (-0.05 %)
DIA $ 399.76 $ 0.74 (0.19 %)
SPY $ 529.24 $ 0.76 (0.14 %)
TLT $ 91.40 $ -0.62 (-0.67 %)
GLD $ 223.63 $ 3.63 (1.65 %)
$ 1.27
$ 1.38
$ 0.00 x 0
$ 0.00 x 0
$ 1.26 - $ 1.38
$ 1.04 - $ 3.23
471,177
na
68.78M
$ 1.02
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-15-2024 03-31-2024 10-Q
2 02-14-2024 12-31-2023 10-Q
3 12-21-2023 09-30-2023 10-K
4 08-10-2023 06-30-2023 10-Q
5 05-12-2023 03-31-2023 10-Q
6 02-14-2023 12-31-2022 10-Q
7 12-27-2022 09-30-2022 10-K
8 08-12-2022 06-30-2022 10-Q
9 05-13-2022 03-31-2022 10-Q
10 02-11-2022 12-31-2021 10-Q
11 12-21-2021 09-30-2021 10-K
12 08-13-2021 06-30-2021 10-Q
13 05-17-2021 03-31-2021 10-Q
14 02-12-2021 12-31-2020 10-Q
15 12-29-2020 09-30-2020 10-K
16 08-10-2020 06-30-2020 10-Q
17 05-08-2020 03-31-2020 10-Q
18 02-10-2020 12-31-2019 10-Q
19 12-16-2019 09-30-2019 10-K
20 08-14-2019 06-30-2019 10-Q
21 05-14-2019 03-31-2019 10-Q
22 02-14-2019 12-31-2018 10-Q
23 12-19-2018 09-30-2018 10-K
24 08-14-2018 06-30-2018 10-Q
25 05-15-2018 03-31-2018 10-Q
26 02-12-2018 12-31-2017 10-Q
27 12-29-2017 09-30-2017 10-K
28 08-09-2017 06-30-2017 10-Q
29 05-10-2017 03-31-2017 10-Q
30 02-09-2017 12-31-2016 10-Q
31 12-14-2016 09-30-2016 10-K
32 08-09-2016 06-30-2016 10-Q
33 05-10-2016 03-31-2016 10-Q
34 02-09-2016 12-31-2015 10-Q
35 12-11-2015 09-30-2015 10-K
36 08-07-2015 06-30-2015 10-Q
37 05-08-2015 03-31-2015 10-Q
38 02-06-2015 12-31-2014 10-Q
39 12-23-2014 09-30-2014 10-K
40 08-08-2014 06-30-2014 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 cel-sci-q2-2024-gaap-eps-028-misses-014-estimate

CEL-SCI (AMEX:CVM) reported quarterly losses of $(0.28) per share which missed the analyst consensus estimate of $(0.14) by 100...

 why-cel-sci-cvm-shares-are-trading-higher

CEL-SCI shares are trading higher by 18.6% during Wednesday's session. The company received positive feedback from the FDA ...

 cel-sci-receives-fda-approval-for-its-confirmatory-study-of-multikine-for-the-treatment-of-head--neck-cancer

Critical milestone achieved—the FDA accepted CEL-SCI's selection criteria defining the Multikine target population before s...

 cel-sci-corporation-issues-letter-to-shareholders

CEL-SCI Corporation (NYSE:CVM) today issued a letter to its shareholders. This letter will be sent to the Company's shareho...

 cel-sci-q1-eps-014-up-from-018-yoy

CEL-SCI (AMEX:CVM) reported quarterly losses of $(0.14) per share. This is a 22.22 percent increase over losses of $(0.18) per ...

 why-cel-sci-corporation-cvm-shares-are-diving

CEL-SCI Corporation shares are trading lower by 13.9% Friday morning. The company priced an offering of 3.875 million shares.

 why-u-power-shares-are-trading-lower-by-around-54-here-are-other-stocks-moving-in-mondays-mid-day-session

Shares of U Power Limited (NASDAQ: UCAR) shares moved lower during Monday’s session after the company announced pricing of reg...

 why-is-cancer-focused-cel-sci-stock-trading-higher-today

CEL-SCI Corporation (AMEX: CVM) announced that the British National Institute for Health and Care Excellence (NICE) has selecte...

 uks-national-institute-for-health-and-care-excellence-selects-cel-scis-multikine-as-potential-new-standard-of-care-for-head--neck-cancer

CEL-SCI Corporation (NYSE:CVM) today announced that the British National Institute for Health and Care Excellence (NICE) has se...

 cel-sci-issues-letter-to-shareholders

CEL-SCI Corporation (NYSE:CVM) today released a letter to shareholders from the Company's CEO, Geert Kersten. The very comp...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION